Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP-151-3
- Development stage
- Preclinical
- Lead developer
- Shaman Ventures
- Modality
- Small Molecules
01
Overview
SP-151-3 is a small molecule drug candidate developed by Shaman Ventures, currently in preclinical development for the treatment of neuropathic pain, fibromyalgia, and diabetic neuropathy. The compound is designed to modulate biological pathways involved in neuropathic pain to inhibit pain signaling. As part of Shaman Ventures' pipeline, it is derived from or inspired by natural products identified through ethnobotanical research. The specific molecular targets of SP-151-3 have not been publicly disclosed, but the drug aims to address chronic pain conditions by targeting pathways implicated in neuropathic pain signaling.
Beyond the preview
Go deeper on SP-151-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP-151-3.